Lifecore Hits Q2 Goals with Strong Pipeline | Business and Finance News

Lifecore Biomedical is on fire—hitting Q2 targets with momentum across growth, development, and new business. Demand from their top client is skyrocketing, projected to double by 2027 and triple by 2028. They cleared a major hurdle with a flawless inspection in Japan, adding credibility for global expansion. Seven audits this quarter? Zero issues. Eleven pipeline programs poised for commercialization by 2028, plus two new launches already in the works. Fresh leadership in project management and manufacturing science is accelerating progress. Six new deals signed, including a late-stage injectable win—thanks in part to FDA tightening and the push toward local manufacturing. Revenues dipped slightly year-over-year, but the second half looks stronger. SG&A expenses are down five quarters in a row, and cash reserves sit at $38M+. Full-year guidance remains intact—this is a company building unstoppable momentum. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/a08725be9a3a8996